Palatin Technologies (PTN) Other Accumulated Expenses (2015 - 2026)
Palatin Technologies' (PTN) quarterly Other Accumulated Expenses came in at $152746.0 in Q1 2026, up 372.62% YoY from $32319.0 in Q1 2025, and up 1823.75% on a QoQ basis from $7940.0 in Q4 2025.
Palatin Technologies (PTN) Other Accumulated Expenses (2015 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 12 years of Other Accumulated Expenses data on file, last reported at $152746.0 in Q1 2026.
- Quarterly Other Accumulated Expenses rose 372.62% year-over-year to $152746.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152746.0 (up 372.62% YoY) and the FY2025 annual result came in at $188769.0, down 80.01% from the prior year.
- Other Accumulated Expenses rose to $152746.0 in Q1 2026, from $7940.0 in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $5.9 million in Q1 2022 to a low of $7940.0 in Q4 2025.
- A 5-year average of $1.6 million and a median of $173549.0 in 2025 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses soared 2765.49% — and 2024, when it sank 99.62%.
- Tracing PTN's Other Accumulated Expenses over 5 years: stood at $123122.0 in 2022, then soared by 2765.49% to $3.5 million in 2023, then slumped by 97.86% to $75403.0 in 2024, then plunged by 89.47% to $7940.0 in 2025, then jumped by 1823.75% to $152746.0 in 2026.
- The last three Other Accumulated Expenses figures came in at $152746.0 (Q1 2026), $7940.0 (Q4 2025), and $173549.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 152,746.00 |
| Dec 31, 2025 | 7,940.00 |
| Sep 30, 2025 | 173,549.00 |
| Jun 30, 2025 | 188,769.00 |
| Mar 31, 2025 | 32,319.00 |
| Dec 31, 2024 | 75,403.00 |
| Sep 30, 2024 | 139,731.00 |
| Jun 30, 2024 | 944,150.00 |
| Mar 31, 2024 | 11,972.00 |
| Dec 31, 2023 | 3.53 Mn |
| Sep 30, 2023 | 3.75 Mn |
| Jun 30, 2023 | 3.86 Mn |
| Mar 31, 2023 | 3.12 Mn |
| Dec 31, 2022 | 123,122.00 |
| Sep 30, 2022 | 5.52 Mn |
| Jun 30, 2022 | 157,390.00 |
| Mar 31, 2022 | 5.93 Mn |
| Dec 31, 2021 | 7.07 Mn |
| Sep 30, 2021 | 209,746.00 |
| Jun 30, 2021 | 185,485.00 |